GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Accumulated other comprehensive income (loss)

Akari Therapeutics (FRA:CLA) Accumulated other comprehensive income (loss) : €-0.72 Mil (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Akari Therapeutics's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was €-0.72 Mil.

Akari Therapeutics's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2024 (€-0.83 Mil) to Dec. 2024 (€-0.71 Mil) but then declined from Dec. 2024 (€-0.71 Mil) to Mar. 2025 (€-0.72 Mil).

Akari Therapeutics's annual Accumulated other comprehensive income (loss) declined from Dec. 2022 (€-0.73 Mil) to Dec. 2023 (€-0.95 Mil) but then increased from Dec. 2023 (€-0.95 Mil) to Dec. 2024 (€-0.71 Mil).

Akari Therapeutics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Akari Therapeutics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Accumulated other comprehensive income (loss) Chart

Akari Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.53 -0.48 -0.73 -0.95 -0.71

Akari Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.70 -0.70 -0.83 -0.71 -0.72

Akari Therapeutics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Akari Therapeutics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
ATRA RNXT MRSN KRON APVO GRCE OSTX NRXP AVTX RNTX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
AKTX:USA
Address
22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210
Website
https://www.akaritx.com
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.